Drospirenone

CHEMBL1509 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
366.5 g/mol
LogP
3.5
Phase
4

A synthetic progestin with antimineralocorticoid and antiandrogenic properties used in hormonal contraceptives and to treat menopausal symptoms. It helps prevent pregnancy, reduces water retention, and may improve acne.

Masse moléculaire

366,5000 g/mol

LogP

3,50

TPSA

43,40 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@H]1[C@@H]3[C@@H]4C[C@@H]4[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@@H]12

InChI

InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1

Molecular Formula

C24H30O3

HBD / HBA

- / 3

Liaisons Rotatives

0

Atomes Lourds

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A synthetic progestin with antimineralocorticoid and antiandrogenic properties used in hormonal contraceptives and to treat menopausal symptoms. It helps prevent pregnancy, reduces water retention, and may improve acne.

Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.

Yes, Drospirenone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1509. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 68873. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.